Argent Bio. Regulatory News (RGT)

29 November 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

ASX Delisting Update

and

Notice of Intention to Delist from the London Stock Exchange

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, wishes to advise, that following a detailed review of both the listing requirements and costs associated with the transfer of all its ordinary shares, from the equity shares (international commercial companies secondary listing) category of the Official List maintained by the Financial Conduct Authority ("FCA") ("Official List"), to the equity shares (commercial companies) ("ESCC") category of the Official List, the Company has decided to retain its listing on the Australian Securities Exchange ("ASX") and apply to the FCA and the London Stock Exchange ("LSE") to cancel the admission of Argent BioPharma's shares to listing in the International Commercial Companies Secondary Listing category of the Official List of the FCA and trading under the ticker "RGT" on the Main Market for listed securities of the LSE.

The Company hereby gives notice that, in an effort to streamline and simplify processes and increase administrative efficiencies, it will requested that (i) the FCA cancel the listing of the Company's ordinary shares of NPV ("Shares") on the equity shares international commercial companies secondary listing segment of the Official List of the FCA, and (ii) the LSE cancel the admission to trading of the Company's Shares on the main market for listed securities of the LSE (collectively, the "Delisting").

In accordance with UK Listing Rule 21.2.17, Argent BioPharma is required to give at least 20 business days' notice of the intended Delisting. It is expected the Delisting will become effective from 08:00 (GMT) on 31 December 2024. The last day of trading of Argent BioPharma shares on the LSE will be Monday, 31 December 2024.

As the Company is assigned to the equity shares international commercial companies secondary listing segment of the Official List, no shareholder approval is required for the Delisting. Following the Delisting, (i) it will no longer be possible to trade Shares on the LSE, and (ii) the Company will maintain its listings on the ASX and OTCQB Venture Market.

Any shareholder with questions regarding the Delisting is encouraged to consult their investment adviser or broker. The Company will provide an update to holders of its Depositary Interests, outlining how their holdings will be affected and the steps required to ensure the future tradability of their securities.

The Company's main operations and management are based in the EU, with a growing investor base in the United States of America. Looking ahead, Argent BioPharma may still look to explore opportunities to expand its accessibility to investors, including the potential for a dual listing on a United States based exchange.

-Ends-

Authorised for release by the board of directors, for further information please contact:

About Argent BioPharma

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the central nervous system ("CNS") and Immunology treatments.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma